Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
United StatesIPO:
18 July 2019Website:
http://www.mirumpharma.comNext earnings report:
02 August 2024Last dividends:
N/ANext dividends:
N/APrice
after hours | Fri, 05 Jul 2024 21:19:50 GMTDividend
Analysts recommendations
Institutional Ownership
MIRM Latest News
Mirum Pharmaceuticals (MIRM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Mirum (MIRM) posts positive interim data from two phase IIb studies evaluating volixibat in patients with primary biliary cholangitis and primary sclerosing cholangitis. Stock rises.
Monday, Mirum Pharmaceuticals Inc. MIRM announced interim results from two Phase 2b studies evaluating volixibat for primary biliary cholangitis (PBC) and primary sclerosing cholangitis (PSC).
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024.
Mirum Pharmaceuticals (MIRM) reported earnings 30 days ago. What's next for the stock?
FOSTER CITY, Calif.--(BUSINESS WIRE)-- #alagillesyndrome--Mirum Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months and Older.
Mirum's (MIRM) lead drug, Livmarli, continues to generate steady sales. The recent label expansion of the drug should drive sales further.
Mirum's (MIRM) Livmarli gets FDA approval for label expansion to include the treatment of cholestatic pruritus in patients aged five years and older with PFIC.
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2023 Earnings Call Transcript
Mirum Pharmaceuticals, Inc. (MIRM) came out with a quarterly loss of $0.66 per share versus the Zacks Consensus Estimate of a loss of $0.34. This compares to loss of $0.99 per share a year ago.
- 1(current)
What type of business is Mirum Pharmaceuticals?
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. The company's lead product candidate is LIVMARLI, an investigational oral drug for the treatment of progressive familial intrahepatic cholestasis disease, as well as for the treatment of Alagille syndrome and biliary atresia disease. It also develops Volixibat drug for treatment of intrahepatic cholestasis of pregnancy and primary sclerosing cholangitis. Mirum Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Foster City, California.
What sector is Mirum Pharmaceuticals in?
Mirum Pharmaceuticals is in the Healthcare sector
What industry is Mirum Pharmaceuticals in?
Mirum Pharmaceuticals is in the Biotechnology industry
What country is Mirum Pharmaceuticals from?
Mirum Pharmaceuticals is headquartered in United States
When did Mirum Pharmaceuticals go public?
Mirum Pharmaceuticals initial public offering (IPO) was on 18 July 2019
What is Mirum Pharmaceuticals website?
https://www.mirumpharma.com
Is Mirum Pharmaceuticals in the S&P 500?
No, Mirum Pharmaceuticals is not included in the S&P 500 index
Is Mirum Pharmaceuticals in the NASDAQ 100?
No, Mirum Pharmaceuticals is not included in the NASDAQ 100 index
Is Mirum Pharmaceuticals in the Dow Jones?
No, Mirum Pharmaceuticals is not included in the Dow Jones index
When does Mirum Pharmaceuticals report earnings?
The next expected earnings date for Mirum Pharmaceuticals is 02 August 2024